Imaging and clinical outcome of non-small cell lung cancer

Gerald Steve Michael Alexander Kerner

Imaging and clinical outcome of non-small cell lung cancer

Gerald Steve Michael Alexander Kerner

Onderzoeksoutput

1886 Downloads (Pure)

Samenvatting

Gerald Kerner, born in Curaçao, showed in his thesis that a specific group of patients with non-small cell lung cancer (NSCLC) treated with the ALK inhibitor crizotinib, in 46% of the cases PET/CT was able to show progressive disease earlier time point compared with CT.
He also showed with a specifiec PET tracer that in NSCLC tumors are dynamically hypoxic. This is related to resistance to therapy. Furthermore, he evaluated a new technique for response assessment with PET/CT in lung cancer. However, he showed that this new technique is not reliable for this type of response assessment.
He also showed that the combination of the chemotherapeutic agent gemcitabine combined with radiotherapy is safe and effective in treating locally advanced NSCLC.
Lastly, he described the frequency of genetic mutations within a NSCLC population in the Northern Netherlands. The presence of these genetic mutations EGFR and KRAS are associated with certain therapeutic choices.

Originele taal-2	English
Kwalificatie	Doctor of Philosophy
Toekennende instantie	Rijksuniversiteit Groningen
Begeleider(s)/adviseur	Groen, Harry, Supervisor Pruim, Jan, Supervisor
Datum van toekenning	11-mei-2016
Plaats van publicatie	[Groningen]
Uitgever	Rijksuniversiteit Groningen
Gedrukte ISBN's	978-90-367-8834-2
Elektronische ISBN's	978-90-367-8833-5
Status	Published - 2016

Toegang tot document

Title and contentsFinal publisher's version, 476 KB
Chapter 1Final publisher's version, 776 KB
Chapter 2Final publisher's version, 4,6 MB
Chapter 3Final publisher's version, 3,48 MB
Chapter 4Final publisher's version, 2,42 MB
Chapter 5Final publisher's version, 1,61 MB
Chapter 6Final publisher's version, 1,68 MB
Chapter 7Final publisher's version, 1,18 MB
Chapter 8Final publisher's version, 1,99 MB
Chapter 9Final publisher's version, 866 KB
Chapter 10Final publisher's version, 928 KB
Curriculum VitaeFinal publisher's version, 618 KB
DankwoordFinal publisher's version, 867 KB
Complete thesisFinal publisher's version, 20,4 MB
PropositionsFinal publisher's version, 43 KB

Handle.net

Permanente koppeling

Citeer dit

@phdthesis{3ed21fc9186e4332b872e5e4ba91a49d,

title = "Imaging and clinical outcome of non-small cell lung cancer",

abstract = "Gerald Kerner, born in Cura{\c c}ao, showed in his thesis that a specific group of patients with non-small cell lung cancer (NSCLC) treated with the ALK inhibitor crizotinib, in 46% of the cases PET/CT was able to show progressive disease earlier time point compared with CT.He also showed with a specifiec PET tracer that in NSCLC tumors are dynamically hypoxic. This is related to resistance to therapy. Furthermore, he evaluated a new technique for response assessment with PET/CT in lung cancer. However, he showed that this new technique is not reliable for this type of response assessment.He also showed that the combination of the chemotherapeutic agent gemcitabine combined with radiotherapy is safe and effective in treating locally advanced NSCLC.Lastly, he described the frequency of genetic mutations within a NSCLC population in the Northern Netherlands. The presence of these genetic mutations EGFR and KRAS are associated with certain therapeutic choices.",

author = "Kerner, {Gerald Steve Michael Alexander}",

year = "2016",

language = "English",

isbn = "978-90-367-8834-2",

publisher = "Rijksuniversiteit Groningen",

school = "University of Groningen",

}

TY - THES

T1 - Imaging and clinical outcome of non-small cell lung cancer

AU - Kerner, Gerald Steve Michael Alexander

PY - 2016

Y1 - 2016

N2 - Gerald Kerner, born in Curaçao, showed in his thesis that a specific group of patients with non-small cell lung cancer (NSCLC) treated with the ALK inhibitor crizotinib, in 46% of the cases PET/CT was able to show progressive disease earlier time point compared with CT.He also showed with a specifiec PET tracer that in NSCLC tumors are dynamically hypoxic. This is related to resistance to therapy. Furthermore, he evaluated a new technique for response assessment with PET/CT in lung cancer. However, he showed that this new technique is not reliable for this type of response assessment.He also showed that the combination of the chemotherapeutic agent gemcitabine combined with radiotherapy is safe and effective in treating locally advanced NSCLC.Lastly, he described the frequency of genetic mutations within a NSCLC population in the Northern Netherlands. The presence of these genetic mutations EGFR and KRAS are associated with certain therapeutic choices.

AB - Gerald Kerner, born in Curaçao, showed in his thesis that a specific group of patients with non-small cell lung cancer (NSCLC) treated with the ALK inhibitor crizotinib, in 46% of the cases PET/CT was able to show progressive disease earlier time point compared with CT.He also showed with a specifiec PET tracer that in NSCLC tumors are dynamically hypoxic. This is related to resistance to therapy. Furthermore, he evaluated a new technique for response assessment with PET/CT in lung cancer. However, he showed that this new technique is not reliable for this type of response assessment.He also showed that the combination of the chemotherapeutic agent gemcitabine combined with radiotherapy is safe and effective in treating locally advanced NSCLC.Lastly, he described the frequency of genetic mutations within a NSCLC population in the Northern Netherlands. The presence of these genetic mutations EGFR and KRAS are associated with certain therapeutic choices.

M3 - Thesis fully internal (DIV)

SN - 978-90-367-8834-2

PB - Rijksuniversiteit Groningen

CY - [Groningen]

ER -